Home » Expertise » Case Study Database » Evaluating an Investment Opportunity for a Drug Product in Gaucher Disease
Evaluating an Investment Opportunity for a Drug Product in Gaucher Disease

Evaluating an Investment Opportunity for a Drug Product in Gaucher Disease

Challenge

With an option to acquire the royalty streams for a product used to treat Gaucher disease, an institutional investor required support in uncovering risks associated with the investment opportunity.

Shift Health’s Role

Using a rapid scan evaluation framework Shift Health previously developed for the client, we examined potential risks related to the product’s safety/efficacy, patent status, competitive threats, payer dynamics and revenue trends. Pricing pressure in the payer environment and a smaller target population compared to entrenched competitors were identified as potential red flags and were investigated further. We developed a report that highlighted key findings and assigned a risk level for the investment opportunity as a whole and for each topic explored.

Impact

Shift Health’s report and the identified investment risks were timely and served as guideposts that focused the client’s further diligence efforts, aiding them in making an investment decision.


In order to download the PDF, please fill out the following form: